Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

A new study found that GLP-1 medications like Ozempic can have some surprising benefits.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Compared with placebo, semaglutide lowered risks for adverse kidney outcomes and mortality across the chronic kidney disease spectrum, according to study data published in Clinical Journal of the ...

While the study highlights potential psychiatric benefits, the medications are linked to known risks including ...

A large-scale study suggests that GLP-1 drugs could have unexpected mental health benefits, including lower risks of ...

A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...

Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a groundbreaking solution for individuals struggling with weight loss. As demand surges ...

Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

AIIMS Professor emphasizes that lifestyle changes are essential, as Semaglutide cannot replace healthy habits for effective ...